Literature DB >> 33431694

Altered ratio of dendritic cell subsets in skin-draining lymph nodes promotes Th2-driven contact hypersensitivity.

Hannah L Miller1, Prabhakar Sairam Andhey1, Melissa K Swiecki2, Bruce A Rosa3,4, Konstantin Zaitsev1,5, Alexandra-Chloe Villani6, Makedonka Mitreva3,4, Maxim N Artyomov1, Susan Gilfillan1, Marina Cella1, Marco Colonna7.   

Abstract

Plasmacytoid dendritic cells (pDCs) specialize in the production of type I IFN (IFN-I). pDCs can be depleted in vivo by injecting diphtheria toxin (DT) in a mouse in which pDCs express a diphtheria toxin receptor (DTR) transgene driven by the human CLEC4C promoter. This promoter is enriched for binding sites for TCF4, a transcription factor that promotes pDC differentiation and expression of pDC markers, including CLEC4C. Here, we found that injection of DT in CLEC4C-DTR+ mice markedly augmented Th2-dependent skin inflammation in a model of contact hypersensitivity (CHS) induced by the hapten fluorescein isothiocyanate. Unexpectedly, this biased Th2 response was independent of reduced IFN-I accompanying pDC depletion. In fact, DT treatment altered the representation of conventional dendritic cells (cDCs) in the skin-draining lymph nodes during the sensitization phase of CHS; there were fewer Th1-priming CD326+ CD103+ cDC1 and more Th2-priming CD11b+ cDC2. Single-cell RNA-sequencing of CLEC4C-DTR+ cDCs revealed that CD326+ DCs, like pDCs, expressed DTR and were depleted together with pDCs by DT treatment. Since CD326+ DCs did not express Tcf4, DTR expression might be driven by yet-undefined transcription factors activating the CLEC4C promoter. These results demonstrate that altered DC representation in the skin-draining lymph nodes during sensitization to allergens can cause Th2-driven CHS.

Entities:  

Keywords:  Th2; allergy; contact hypersensitivity; plasmacytoid DC; skin

Mesh:

Substances:

Year:  2021        PMID: 33431694      PMCID: PMC7826349          DOI: 10.1073/pnas.2021364118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  49 in total

1.  Plasmacytoid dendritic cells and cancer.

Authors:  William Vermi; Matias Soncini; Laura Melocchi; Silvano Sozzani; Fabio Facchetti
Journal:  J Leukoc Biol       Date:  2011-07-05       Impact factor: 4.962

Review 2.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.

Authors:  Miriam Merad; Priyanka Sathe; Julie Helft; Jennifer Miller; Arthur Mortha
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

Review 3.  Early immune events in the induction of allergic contact dermatitis.

Authors:  Daniel H Kaplan; Botond Z Igyártó; Anthony A Gaspari
Journal:  Nat Rev Immunol       Date:  2012-01-13       Impact factor: 53.106

4.  Toll-like receptor 9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity.

Authors:  Christina Li-Ping Thio; Alan Chuan-Ying Lai; Po-Yu Chi; Gill Webster; Ya-Jen Chang
Journal:  J Allergy Clin Immunol       Date:  2019-03-23       Impact factor: 10.793

5.  Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection.

Authors:  Khuong B Nguyen; Wendy T Watford; Rachelle Salomon; Sigrun R Hofmann; Gary C Pien; Akio Morinobu; Massimo Gadina; John J O'Shea; Christine A Biron
Journal:  Science       Date:  2002-09-20       Impact factor: 47.728

6.  CD326(lo)CD103(lo)CD11b(lo) dermal dendritic cells are activated by thymic stromal lymphopoietin during contact sensitization in mice.

Authors:  Sotaro Ochiai; Ben Roediger; Arby Abtin; Elena Shklovskaya; Barbara Fazekas de St Groth; Hidehiro Yamane; Wolfgang Weninger; Graham Le Gros; Franca Ronchese
Journal:  J Immunol       Date:  2014-07-23       Impact factor: 5.422

7.  IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation.

Authors:  Emma K Persson; Heli Uronen-Hansson; Monika Semmrich; Aymeric Rivollier; Karin Hägerbrand; Jan Marsal; Sigurdur Gudjonsson; Ulf Håkansson; Boris Reizis; Knut Kotarsky; William W Agace
Journal:  Immunity       Date:  2013-05-09       Impact factor: 31.745

8.  Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients.

Authors:  Vanja Sisirak; Julien Faget; Nelly Vey; Jean-Yves Blay; Christine Ménétrier-Caux; Christophe Caux; Nathalie Bendriss-Vermare
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

9.  Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells.

Authors:  Claudia U Duerr; Connor D A McCarthy; Barbara C Mindt; Manuel Rubio; Alexandre P Meli; Julien Pothlichet; Megan M Eva; Jean-François Gauchat; Salman T Qureshi; Bruce D Mazer; Karen L Mossman; Danielle Malo; Ana M Gamero; Silvia M Vidal; Irah L King; Marika Sarfati; Jörg H Fritz
Journal:  Nat Immunol       Date:  2015-11-23       Impact factor: 31.250

10.  cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity.

Authors:  Stephen T Ferris; Vivek Durai; Renee Wu; Derek J Theisen; Jeffrey P Ward; Michael D Bern; Jesse T Davidson; Prachi Bagadia; Tiantian Liu; Carlos G Briseño; Lijin Li; William E Gillanders; Gregory F Wu; Wayne M Yokoyama; Theresa L Murphy; Robert D Schreiber; Kenneth M Murphy
Journal:  Nature       Date:  2020-08-12       Impact factor: 49.962

View more
  2 in total

1.  Lymph node-resident dendritic cells drive TH2 cell development involving MARCH1.

Authors:  Carlos A Castellanos; Xin Ren; Steven Lomeli Gonzalez; Hong Kun Li; Andrew W Schroeder; Hong-Erh Liang; Brian J Laidlaw; Donglei Hu; Angel C Y Mak; Celeste Eng; José R Rodríguez-Santana; Michael LeNoir; Qi Yan; Juan C Celedón; Esteban G Burchard; Scott S Zamvil; Satoshi Ishido; Richard M Locksley; Jason G Cyster; Xiaozhu Huang; Jeoung-Sook Shin
Journal:  Sci Immunol       Date:  2021-10-15

2.  Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade.

Authors:  Ying Zhang; Raghava N Sriramaneni; Paul A Clark; Justin C Jagodinsky; Mingzhou Ye; Wonjong Jin; Yuyuan Wang; Amber Bates; Caroline P Kerr; Trang Le; Raad Allawi; Xiuxiu Wang; Ruosen Xie; Thomas C Havighurst; Ishan Chakravarty; Alexander L Rakhmilevich; Kathleen A O'Leary; Linda A Schuler; Paul M Sondel; Kyungmann Kim; Shaoqin Gong; Zachary S Morris
Journal:  Nat Commun       Date:  2022-08-23       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.